Section Arrow
Quote
IKT.NASDAQ
- Inhibikase Therapeutics
Quotes are at least 15-min delayed:2026/04/21 21:21 EDT
Regular Hours
Last
 1.67
-0.14 (-7.73%)
Day High 
1.8 
Prev. Close
1.81 
1-M High
1.9216 
Volume 
2.59M 
Bid
1.7
Ask
1.71
Day Low
1.63 
Open
1.79 
1-M Low
1.57 
Market Cap 
238.98M 
Currency 美元 
P/E 3.62 
%Yield -- 
10-SMA 1.74 
20-SMA 1.72 
50-SMA 1.81 
52-W High 2.365 
52-W Low 1.33 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.49/-0.62
Enterprise Value
238.98M
Balance Sheet
Book Value Per Share
1.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.